Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
IPO Year:
Exchange: NASDAQ
Website: processapharmaceuticals.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2024 | $8.00 | Buy | H.C. Wainwright |
| 8/3/2021 | $20.00 | Outperform | Oppenheimer |
| 8/2/2021 | $20.00 | Outperform | Oppenheimer |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage of AirGate PCS with a rating of Buy and set a new price target of $8.00
Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00
Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00
DEFA14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
SCHEDULE 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
SCHEDULE 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
8-K/A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
DEF 14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
PRER14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
10-Q - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
Fastest customizable press release news feed in the world
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives. We believe that strategic engagement with emerging financial technologies, including select cryptocurrencies with potential yield-generating capabilities, may offer novel avenues to diversify our capital base and enhance financial flexibility, while providing an opportunity for long-term value crea
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of PCS6422Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities. "We are taking deliberate steps to focus our resources on programs with the highest potential for clinical success and commercial impact," said Dr. David Young, President Research and Development at Processa. "Our approach c
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (the "Company"), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant. The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter. The closing of the offer
$452.5 million in total milestone payments$2.5 million in near-term paymentsDouble-digit royalties on future net product sales3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), today announced that it has entered into a binding term sheet with Intact Therapeutics, Inc. ("Intact") granting Intact the exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist with the potential to become a first meaningful treatment for gastroparesis and other gastrointestinal motility disorders. Under the terms of the agreement, Processa is eligible to receive a $2.5 million option exercise fee, up to $20
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leadership team will attend and participate in the 2025 BIO International Convention, taking place June 16-19, 2025, in Boston, Massachusetts. During the conference, Processa's CEO, Georg Ng and Dr. David Young, President R&D will conduct one-on-one meetings with potential partners, investors, and other industry stakeholders to provide updates on the company's strategic direction and clinical progress. Discussions will highlight the advancement of Processa's NGC
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the acceptance of three abstracts for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. The abstracts highlight Processa's pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances. Trials in Progress Poster Presentation and Abstract Publication Abstract
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025. Dr. Young's presentation, titled "Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases," will take place on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the Boston Convention & Exhibition Center. Dr. Young's presentation will explore how
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley's law office in New York City. Management will present a corporate overview on Friday, March 28th at 9:40 a.m. Eastern time, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. The presentation will be available on Processa's website. For more information
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encou
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the closing of its previously announced "reasonable best efforts" public offering with participation from the Company's Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,05
Live Leadership Updates
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Russell L. Skibsted as Chief Financial Officer (CFO), effective immediately. Mr. Skibsted succeeds James Stanker, who is retiring and staying on in an advisory role to assist in the transition. "We are delighted to welcome Russell to Processa's executive team. His proven record in finance and capital markets combined with a deep understanding of the complexities inherent in the life sciences make him a
FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design HANOVER, MD, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it plans to expand the development of Next Generation Capecitabine ("NGC-Cap") into the treatment of advanced or metastatic breast cancer beginning with its ne
HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran George Ng has been appointed to serve as the Company's Chief Executive Officer and as a Board Director as of August 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy (NGC) drugs as President of Research and Development and as a board member. "We are thrilled to have George assume the leadership of ou
Board Appointments Designed to Position Company for Anticipated Milestones While Ensuring Adherence to the Highest Governance Standards HANOVER, MD, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical stage biopharmaceutical company using its Regulatory Science process to more effectively develop products to improve the survival and/or quality of life for patients who have an unmet medical need condition announced today the appointment of Khoso Baluch and James Neal to its Board of Directors. In addition to the two new Independent Directors, current board member Justin Yorke has been named Chairman of the Board. Justin Yorke, Processa Chairman state
This live feed shows all institutional transactions in real time.
Live finance-specific insights
SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
SC 13G - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri's ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and nine months ended September 30, 2024. "We continued to make progres
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and six mont
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: March 30, 2023Time: 4:30 p.m. ETToll Free: 888-506-0062Internatio
PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023.Next Generation Capecitabine (a combination of PCS6422 and capecitabine) successfully identifies dosing regimens for a Phase 2B trial to be initiated in 2023 after a meeting with FDA to discuss the alignment of the trial design with the FDA's Project Optimus Oncology Initiative. HANOVER, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient's
HANOVER, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: November 8, 2022Time: 4:30 p.m. ESTToll Free: 888-506-0062International: 973-528-0011En
PCS12852 on target to complete enrollment by SeptemberExpanded efforts to increase enrollment in PCS499 and PCS6422 showing results HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient's survival and/or quality of life, today announced financial results for the quarter ended June 30, 2022, and provided an update on its clinical programs. Dr. David Young, President and CEO of Processa, commented, "Our efforts to enhance enrollment through adding new sites, extensive marke
HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on August 11, 2022, at 4:30 p.m. EST to discuss its second quarter 2022 results and provide an update on its clinical pipeline. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: August 11, 2022Time: 4:30 p.m. ETToll Free: 877-545-0320International: 973-528-0002 Ent
Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in PCS499PCS12852 on target to complete enrollment by Q3 HANOVER, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient's survival and/or quality of life, today announced financial results for the quarter ended March 31, 2022, and provided an update on its clinical programs. Dr. David Young, CEO and chairman of Processa, commented
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on May 12, 2022 at 4:30 p.m. EST to discuss its results for the first quarter and provide an update on its clinical pipeline. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: May 12, 2022Time: 4:30 p.m. ETToll Free: 877-545-0320International: 973-528-0002 Ent
Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient's survival and/or quality of life, today announced financial results for the year ended December 31, 2021, and provided a corporate update. Dr. David Young, CEO and chairman of Processa, commented, "Although COVID presented challenges for us and our industry in 2021, we commenced and enrolled patients in PCS499 for the treatment of uNL, PCS6422 (Next Generation Capecitabine) for the t